• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
AKTS

AKTS

Aktis Oncology, Inc.

NASDAQHealthcareBiotechnologyUS

USD19.37

-0.89 (-4.39%)

Rating:C+

Company Profile

CEO

Matthew Roden

IPO Date

2026-01-09

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$20.29

Prev. Close

$20.26

Day Low

$19.12

Day High

$21.12

52W Low

$14.72

52W High

$29.16

Market Cap

$1.03B

Volume

0.27M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

47.8%

Avg Negative

1.6%

Avg Neutral

50.3%

News Feed

Akoustis Receives Volume Development Order from Tier-1 PC Chipset Company for a WiFi 6E Diplexer

GlobeNewsWire·7/14/2021·↑ positive

Akoustis Signs First Foundry Agreement with 5G Mobile RF Front-End Customer

GlobeNewsWire·6/21/2021·↑ positive

Akoustis Receives WiFi 6E Design Win from New Tier-1 Customer

GlobeNewsWire
·6/17/2021
·↑ positive

Akoustis CEO & Founder, Jeff Shealy, Scheduled to Appear on Fox Business Network's The Claman Countdown Today at 3:30 pm ET

GlobeNewsWire·6/3/2021·↑ positive

U.S. Senate Majority Leader Charles E. Schumer to Speak Today at Akoustis Technologies' Semiconductor Wafer Fab in Upstate New York

GlobeNewsWire·6/2/2021·↑ positive

Akoustis to Present at the 16th Annual Needham Virtual Technology & Media Conference on May 18, 2021 at 8:00 am ET

GlobeNewsWire·5/10/2021·↑ positive

Akoustis (AKTS) Reports Q3 Loss, Tops Revenue Estimates

Zacks Investment Research·5/3/2021·↑ positive

Akoustis Locks Process Flow for Second Wafer Level Package for XBAW Filters

GlobeNewsWire·5/3/2021·↑ positive

Akoustis Reports Record Third Quarter Fiscal 2021 Revenue

GlobeNewsWire·5/3/2021·↑ positive

Akoustis to Webcast Investor Update Call on May 3rd at 8:00 am ET

GlobeNewsWire·4/26/2021·↑ positive